Goldman Sachs’s NovoCure NVCR Stock Holding History

Goldman Sachs’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,300	Closed	-$548K	–	6811
2021 Q4	$548K	Hold	7,300	–	–	﹤0.01%	5310
2021 Q3	$848K	Hold	7,300	–	–	﹤0.01%	4881
2021 Q2	$1.62M	Hold	7,300	–	–	﹤0.01%	4384
2021 Q1	$965K	Hold	7,300	–	–	﹤0.01%	4643
2020 Q4	$1.26M	Hold	7,300	–	–	﹤0.01%	4046
2020 Q3	$813K	Buy	+7,300	New	+$584K	﹤0.01%	4210
2016 Q2	–	Sell	-24,900	Closed	-$361K	–	7175
2016 Q1	$361K	Sell	24,900 -16,100	-39%	-$231K	﹤0.01%	5075
2015 Q4	$917K	Buy	+41,000	New	+$979K	﹤0.01%	4385

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Goldman Sachs's NVCR Position: Q2 2026 in Review

Goldman Sachs increased its NovoCure (NVCR) stake by 29% in Q2 2026, buying an estimated $3.31M and bringing the position to 963,917 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2939.

Goldman Sachs first reported a position in NVCR in Q4 2015 and has held it in 43 quarters since. The position peaked at $97M in Q3 2017. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Goldman Sachs held 963,917 shares of NovoCure worth $14.6M as of Q2 2026.
Goldman Sachs bought 218,482 NovoCure shares in Q2 2026, an estimated $3.31M.
NovoCure made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2939 holding.
Goldman Sachs first reported a position in NovoCure in Q4 2015 and has held it in 43 quarters since.
Goldman Sachs's NovoCure position peaked at $97M in Q3 2017.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.